PL2847228T3 - Przeciwciała zdolne do wiązania się z czynnikiem krzepnięcia XI i/lub jego aktywowaną postacią, czynnikiem Xla oraz ich zastosowanie - Google Patents
Przeciwciała zdolne do wiązania się z czynnikiem krzepnięcia XI i/lub jego aktywowaną postacią, czynnikiem Xla oraz ich zastosowanieInfo
- Publication number
- PL2847228T3 PL2847228T3 PL13721746T PL13721746T PL2847228T3 PL 2847228 T3 PL2847228 T3 PL 2847228T3 PL 13721746 T PL13721746 T PL 13721746T PL 13721746 T PL13721746 T PL 13721746T PL 2847228 T3 PL2847228 T3 PL 2847228T3
- Authority
- PL
- Poland
- Prior art keywords
- binding
- antibodies capable
- activated form
- form factor
- xia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12167438 | 2012-05-10 | ||
| EP12181697 | 2012-08-24 | ||
| EP13150361 | 2013-01-07 | ||
| US201361817675P | 2013-04-30 | 2013-04-30 | |
| EP13721746.9A EP2847228B1 (en) | 2012-05-10 | 2013-05-08 | Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof |
| PCT/EP2013/059618 WO2013167669A1 (en) | 2012-05-10 | 2013-05-08 | Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2847228T3 true PL2847228T3 (pl) | 2019-03-29 |
Family
ID=49550177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13721746T PL2847228T3 (pl) | 2012-05-10 | 2013-05-08 | Przeciwciała zdolne do wiązania się z czynnikiem krzepnięcia XI i/lub jego aktywowaną postacią, czynnikiem Xla oraz ich zastosowanie |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US9783614B2 (https=) |
| EP (2) | EP2847228B1 (https=) |
| JP (2) | JP6348900B2 (https=) |
| KR (1) | KR102060376B1 (https=) |
| CN (1) | CN104684932B (https=) |
| AR (1) | AR091024A1 (https=) |
| AU (2) | AU2013258043B2 (https=) |
| BR (1) | BR112014027952B1 (https=) |
| CA (1) | CA2872926C (https=) |
| DK (1) | DK2847228T3 (https=) |
| ES (1) | ES2698950T3 (https=) |
| HR (1) | HRP20181680T1 (https=) |
| HU (1) | HUE040580T2 (https=) |
| IL (1) | IL235238B (https=) |
| LT (1) | LT2847228T (https=) |
| MX (1) | MX362454B (https=) |
| NZ (1) | NZ701121A (https=) |
| PL (1) | PL2847228T3 (https=) |
| RS (1) | RS57889B1 (https=) |
| SG (2) | SG10201609322QA (https=) |
| SI (1) | SI2847228T1 (https=) |
| TW (2) | TWI644925B (https=) |
| WO (1) | WO2013167669A1 (https=) |
| ZA (1) | ZA201407784B (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011504371A (ja) | 2007-11-21 | 2011-02-10 | オレゴン ヘルス アンド サイエンス ユニバーシティー | 抗第ｘｉ因子モノクローナル抗体およびその使用方法 |
| PT2373691T (pt) | 2008-12-18 | 2019-05-08 | Univ Vanderbilt | Anticorpos anti-fxi e métodos de utilização |
| EP2766347B1 (en) | 2011-10-14 | 2016-05-04 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| JP6033319B2 (ja) | 2011-10-14 | 2016-11-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ＸＩａ因子阻害剤としての置換テトラヒドロイソキノリン化合物 |
| WO2013055984A1 (en) | 2011-10-14 | 2013-04-18 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| EP2847228B1 (en) | 2012-05-10 | 2018-07-25 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof |
| EP2906552B1 (en) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| TR201807316T4 (tr) | 2012-10-12 | 2018-06-21 | Bristol Myers Squibb Co | Bir faktör XIa inhibitörünün kristalli formları. |
| US9403774B2 (en) | 2012-10-12 | 2016-08-02 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| WO2014160668A1 (en) | 2013-03-25 | 2014-10-02 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors |
| NO2760821T3 (https=) | 2014-01-31 | 2018-03-10 | ||
| SG10201908467RA (en) | 2014-01-31 | 2019-10-30 | Bristol Myers Squibb Co | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors |
| WO2016020880A2 (en) | 2014-08-07 | 2016-02-11 | Novartis Ag | Angiopoietin-like 4 antibodies and methods of use |
| WO2016020882A2 (en) | 2014-08-07 | 2016-02-11 | Novartis Ag | Angiopoetin-like 4 (angptl4) antibodies and methods of use |
| ES2714283T3 (es) | 2014-09-04 | 2019-05-28 | Bristol Myers Squibb Co | Macrociclos de diamida que son inhibidores de FXIa |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| CN107405399B (zh) | 2015-01-02 | 2022-02-08 | 武田药品工业株式会社 | 针对血浆激肽释放酶和因子xii的双特异性抗体 |
| UY36751A (es) * | 2015-06-26 | 2017-01-31 | Novartis Ag | Anticuerpos de factor xi y métodos de uso |
| AU2016297018B9 (en) | 2015-07-21 | 2022-12-01 | Takeda Pharmaceutical Company Limited | A monoclonal antibody inhibitor of factor XIIa |
| US11066481B2 (en) | 2015-07-23 | 2021-07-20 | The Regents Of The University Of California | Antibodies to coagulation factor XIa and uses thereof |
| RU2757314C2 (ru) * | 2016-01-22 | 2021-10-13 | Мерк Шарп И Доум Корп. | Антитела против фактора свертывания xi |
| US11059905B2 (en) | 2016-03-23 | 2021-07-13 | Prothix B.V. | Monoclonal antibodies against the active site of factor XI and uses thereof |
| TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
| IL315266A (en) | 2016-06-14 | 2024-10-01 | Merck Sharp ַ& Dohme Llc | Anti-coagulation factor xi antibodies |
| WO2018054813A1 (en) * | 2016-09-20 | 2018-03-29 | Bayer Pharma Aktiengesellschaft | Novel antibodies against factor xi and uses thereof |
| US20200054719A1 (en) * | 2016-11-02 | 2020-02-20 | Erik Ian Tucker | E-we thrombin analog and fibrinolytic combination |
| AU2017383232B2 (en) | 2016-12-23 | 2024-09-12 | Novartis Ag | Factor XI antibodies and methods of use |
| IL267519B2 (en) * | 2016-12-23 | 2025-04-01 | Novartis Ag | Factor XI/XIA for use in the prevention, treatment, management, or reduction of the risk of stroke or thromboembolism in a patient with end-stage renal disease |
| US20190367636A1 (en) | 2017-01-19 | 2019-12-05 | Bayer Pharma Aktiengesellschaft | Novel stable formulation for fxia antibodies |
| US11958911B2 (en) | 2017-02-10 | 2024-04-16 | Shanghai Benemae Pharmaceutical | Anti-coagulation factor XI antibody |
| CN108409863B (zh) * | 2017-02-10 | 2023-09-26 | 上海仁会生物制药股份有限公司 | 抗凝血因子xi抗体 |
| EP3713965A1 (en) * | 2017-11-22 | 2020-09-30 | Novartis AG | Reversal binding agents for anti-factor xi/xia antibodies and uses thereof |
| PE20210462A1 (es) * | 2018-07-05 | 2021-03-08 | Bayer Ag | METODO PARA LA PRODUCCION DE GRANULOS LIOFILIZADOS QUE COMPRENDEN UN ANTICUERPO ANTI-FACTOR XIa (FXIa) DE LA COAGULACION |
| AU2019313550B2 (en) * | 2018-08-01 | 2024-02-08 | Novo Nordisk A/S | Improved procoagulant antibodies |
| ES3016309T3 (en) | 2018-08-07 | 2025-05-08 | Nippon Telegraph & Telephone | Optical transport system |
| CN114478781B (zh) * | 2018-08-09 | 2024-04-02 | 上海仁会生物制药股份有限公司 | 抗凝血因子xi抗体 |
| EP3852820B1 (en) | 2018-09-17 | 2024-11-20 | Board of Regents, The University of Texas System | Compositions and methods for treating bone injury |
| CA3117856A1 (en) | 2018-10-31 | 2020-05-07 | Bayer Aktiengesellschaft | Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies |
| WO2020154234A1 (en) | 2019-01-21 | 2020-07-30 | Aronora Inc. | Novel humanized antibodies against factor xi having anti-thrombotic and anti-inflammatory effects and uses thereof |
| KR20210151774A (ko) | 2019-04-16 | 2021-12-14 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | 항-FXI/FXIa 항체 및 그 용도 |
| CN110423278B (zh) * | 2019-08-08 | 2020-07-17 | 上海博槿生物科技有限公司 | 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用 |
| JP2023106635A (ja) | 2020-04-17 | 2023-08-02 | 中外製薬株式会社 | 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法 |
| EP4177274A4 (en) * | 2020-07-02 | 2024-04-03 | Beijing Tuo Jie Biopharmaceutical Co. Ltd. | Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof |
| CN120858120A (zh) * | 2022-12-30 | 2025-10-28 | 甘李药业股份有限公司 | 抗凝血因子XI和/或其活化形式因子XIa的抗体及其用途 |
| CN119454938B (zh) * | 2024-11-15 | 2025-07-25 | 广州骐骥生物科技有限公司 | 一种枸橼酸透析浓缩液及其制备方法 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5877289A (en) | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
| DE4319041A1 (de) | 1992-10-23 | 1994-04-28 | Bayer Ag | Trisubstituierte Biphenyle |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| US20030235587A1 (en) | 1998-08-07 | 2003-12-25 | Feuerstein Giora Z. | Anticoagulant agents useful in treatment of thrombosis |
| DE19642255A1 (de) | 1996-10-14 | 1998-04-16 | Bayer Ag | Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten |
| US6166027A (en) | 1996-10-14 | 2000-12-26 | Bayer Aktiengesellschaft | Heterocyclylmethyl-substituted pyrazole derivatives and their use for treating cardiovascular diseases |
| DE19649460A1 (de) | 1996-11-26 | 1998-05-28 | Bayer Ag | Neue substituierte Pyrazolderivate |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834045A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| WO2000007626A1 (en) | 1998-08-07 | 2000-02-17 | Smithkline Beecham Corporation | Use of anti-coagulation factor antibodies as long-lasting protective agents |
| DE19846514A1 (de) | 1998-10-09 | 2000-04-20 | Bayer Ag | Neue Heterocyclyl-methyl-substituierte Pyrazole |
| DE19920352A1 (de) | 1999-05-04 | 2000-11-09 | Bayer Ag | Substituiertes Pyrazolderivat |
| DE19942809A1 (de) | 1999-09-08 | 2001-03-15 | Bayer Ag | Verfahren zur Herstellung substituierter Pyrimidinderivate |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| WO2003013423A2 (en) | 2001-08-05 | 2003-02-20 | Gvg, Inc. | Antithrombotic agent |
| US7270976B2 (en) | 2004-07-19 | 2007-09-18 | American Diagnostica, Inc. | Methods for measuring ADAMTS13 activity and protein on platelets and in plasma |
| US20080138837A1 (en) | 2004-07-19 | 2008-06-12 | Robert Greenfield | Methods and kits for detecting and measuring ADAMTS13/FXI complexes |
| US7279513B2 (en) | 2004-11-19 | 2007-10-09 | Nalco Company | Preparation of neutralized ethylene-acrylic acid polymer dispersions and use in printing media for improvement of digital toner adhesion |
| DE102005050376A1 (de) | 2005-10-21 | 2007-05-31 | Bayer Healthcare Ag | Dicarbonsäure-Derivate und ihre Verwendung |
| DE102005050497A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Difluorphenol-Derivate und ihre Verwendung |
| DE102005050375A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Tetrazol-Derivate und ihre Verwendung |
| DE102005050377A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Heterocyclische Verbindungen und ihre Verwendung |
| DE102005050498A1 (de) | 2005-10-21 | 2007-06-06 | Bayer Healthcare Aktiengesellschaft | Cyclopropylessigsäure-Derivate und ihre Verwendung |
| AR064801A1 (es) | 2006-08-18 | 2009-04-29 | Xoma Technology Ltd | Anticuerpo especifico prlr (receptor de prolactina) y sus usos |
| WO2008133857A1 (en) | 2007-04-23 | 2008-11-06 | Schering Corporation | Anti-mdl-1 antibodies |
| US8574849B2 (en) | 2007-10-03 | 2013-11-05 | The University Of Vermont And State Agriculture College | Methods of detection of factor XIa and tissue factor |
| JP2011504371A (ja) * | 2007-11-21 | 2011-02-10 | オレゴン ヘルス アンド サイエンス ユニバーシティー | 抗第ｘｉ因子モノクローナル抗体およびその使用方法 |
| TR201820051T4 (tr) * | 2008-06-19 | 2019-01-21 | Prothix Bv | Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması |
| AU2009322836B2 (en) | 2008-11-25 | 2013-04-04 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| PT2373691T (pt) * | 2008-12-18 | 2019-05-08 | Univ Vanderbilt | Anticorpos anti-fxi e métodos de utilização |
| US8637454B2 (en) | 2009-01-06 | 2014-01-28 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| KR20140019004A (ko) | 2010-05-27 | 2014-02-13 | 머크 샤프 앤드 돔 코포레이션 | 가용성 구아닐레이트 시클라제 활성화제 |
| EP2687210A1 (de) | 2010-06-25 | 2014-01-22 | Bayer Intellectual Property GmbH | Verwendung von Stimulatoren und Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Sichelzellanämie und Konservierung von Blutersatzstoffen |
| EA201390060A1 (ru) | 2010-07-09 | 2013-07-30 | Байер Интеллектуэль Проперти Гмбх | Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| JP6005134B2 (ja) | 2011-04-21 | 2016-10-12 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | フルオロアルキル置換ピラゾロピリジンおよびその使用 |
| CA2834901A1 (en) | 2011-05-06 | 2012-11-15 | Bayer Intellectual Property Gmbh | Substituted imidazopyridines and imidazopyridazines and the use thereof |
| JP6096778B2 (ja) | 2011-09-01 | 2017-03-15 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ピロロピラジンキナーゼ阻害剤 |
| CN104039784B (zh) | 2011-09-02 | 2017-08-22 | 拜耳知识产权有限责任公司 | 取代的增环嘧啶及其用途 |
| EP2847228B1 (en) * | 2012-05-10 | 2018-07-25 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof |
-
2013
- 2013-05-08 EP EP13721746.9A patent/EP2847228B1/en active Active
- 2013-05-08 SI SI201331209T patent/SI2847228T1/sl unknown
- 2013-05-08 CA CA2872926A patent/CA2872926C/en active Active
- 2013-05-08 AU AU2013258043A patent/AU2013258043B2/en not_active Ceased
- 2013-05-08 EP EP18176293.1A patent/EP3404045A1/en not_active Withdrawn
- 2013-05-08 JP JP2015510818A patent/JP6348900B2/ja active Active
- 2013-05-08 US US14/400,281 patent/US9783614B2/en active Active
- 2013-05-08 NZ NZ701121A patent/NZ701121A/en not_active IP Right Cessation
- 2013-05-08 DK DK13721746.9T patent/DK2847228T3/en active
- 2013-05-08 MX MX2014013568A patent/MX362454B/es active IP Right Grant
- 2013-05-08 BR BR112014027952-7A patent/BR112014027952B1/pt not_active IP Right Cessation
- 2013-05-08 SG SG10201609322QA patent/SG10201609322QA/en unknown
- 2013-05-08 HR HRP20181680TT patent/HRP20181680T1/hr unknown
- 2013-05-08 RS RS20181219A patent/RS57889B1/sr unknown
- 2013-05-08 HU HUE13721746A patent/HUE040580T2/hu unknown
- 2013-05-08 WO PCT/EP2013/059618 patent/WO2013167669A1/en not_active Ceased
- 2013-05-08 SG SG11201406719UA patent/SG11201406719UA/en unknown
- 2013-05-08 KR KR1020147034253A patent/KR102060376B1/ko not_active Expired - Fee Related
- 2013-05-08 ES ES13721746T patent/ES2698950T3/es active Active
- 2013-05-08 LT LTEP13721746.9T patent/LT2847228T/lt unknown
- 2013-05-08 CN CN201380037161.1A patent/CN104684932B/zh active Active
- 2013-05-08 PL PL13721746T patent/PL2847228T3/pl unknown
- 2013-05-09 TW TW106143305A patent/TWI644925B/zh not_active IP Right Cessation
- 2013-05-09 TW TW102116466A patent/TWI631140B/zh not_active IP Right Cessation
- 2013-05-10 AR ARP130101638A patent/AR091024A1/es not_active Application Discontinuation
-
2014
- 2014-10-21 IL IL235238A patent/IL235238B/en active IP Right Grant
- 2014-10-24 ZA ZA2014/07784A patent/ZA201407784B/en unknown
-
2017
- 2017-08-30 US US15/691,731 patent/US10221247B2/en active Active
- 2017-08-30 US US15/691,736 patent/US10040866B2/en active Active
-
2018
- 2018-02-06 AU AU2018200850A patent/AU2018200850C1/en not_active Ceased
- 2018-06-01 JP JP2018106275A patent/JP2018148920A/ja active Pending
-
2019
- 2019-03-04 US US16/292,196 patent/US11046783B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201407784B (en) | Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof | |
| IL256716A (en) | Antibodies against hla–b*27 and their uses | |
| IL236838A0 (en) | Antibodies against dengue virus and uses thereof | |
| IL238559B (en) | Antibodies against ceacam5 and their use | |
| IL254416B (en) | Anti-asic1 antibodies and their uses | |
| ZA201500872B (en) | Rspo3 binding agents and uses thereof | |
| PL3354751T3 (pl) | Przeciwciała dla arypiprazolu i ich zastosowanie | |
| EP2888590A4 (en) | ANTIBODIES AGAINST OLANZAPINE AND USE THEREOF | |
| GB201219487D0 (en) | Anti-S100A4 antibody molecules and their uses | |
| LT2999714T (lt) | Surišančios molekulės, kurios suriša žmogaus komplemento faktorių c2 ir jų panaudojimas | |
| PT2847228T (pt) | Anticorpos com capacidade de se ligarem ao fator xi de coagulação e/ou à sua forma ativada fator xia e utilizações dos mesmos | |
| GB201208372D0 (en) | Antibodies and uses thereof |